Rajni K Jani

age ~72

from Fort Worth, TX

Get Report

Also known as:

Connected to:

Rajni Jani Phones & Addresses

r***[email protected]

view source

Name / Title

Company / Classification

Phones & Addresses

Rajni Jani
Director

KAMYA PERFORMING ARTS ACADEMY, INC
Elementary/Secondary School

6016 Annandale Dr, Fort Worth, TX 76132

Olopatadine Formulations For Topical Nasal Administration
view source
US Patent:

7977376, Jul 12, 2011
Filed:

Feb 7, 2007
Appl. No.:

11/703373
Inventors:

Onkar N. Singh - Arlington TX, US
G. Michael Wall - Fort Worth TX, US
Rajni Jani - Fort Worth TX, US
Masood A. Chowhan - Arlington TX, US
Wesley Wehsin Han - Arlington TX, US
Assignee:

Novartis AG - Basal
International Classification:

A61K 31/335
US Classification:

514450, 424810
Abstract:

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0. 6% (w/v) of olopatadine.

Olopatadine Formulations For Topical Nasal Administration
view source
US Patent:

8399508, Mar 19, 2013
Filed:

Jun 30, 2011
Appl. No.:

13/173608
Inventors:

Onkar N. Singh - Arlington TX, US
G. Michael Wall - Fort Worth TX, US
Rajni Jani - Fort Worth TX, US
Masood A. Chowhan - Arlington TX, US
Wesley Wehsin Han - Arlington TX, US
Assignee:

Alcon Pharmaceuticals Ltd. - Fribourg
International Classification:

A61K 31/335
US Classification:

514450, 424810
Abstract:

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0. 6% (w/v) of olopatadine.

Use Of An Anti-Allergy Agent And A Steroid To Treat Nasal Conditions
view source
US Patent:

20040097474, May 20, 2004
Filed:

Nov 12, 2003
Appl. No.:

10/706759
Inventors:

Gerald Cagle - Fort Worth TX, US
G. Wall - Fort Worth TX, US
John Yanni - Burleson TX, US
Rajni Jani - Fort Worth TX, US
Haresh Bhagat - Fort Worth TX, US
Assignee:

Alcon, Inc.
International Classification:

A61K031/573
A61L009/04
A61K009/14
US Classification:

514/171000, 424/046000
Abstract:

Compositions and methods for treating rhinitis with certain combinations of antiallergic agents and steroids are disclosed.

Formulations Of Glucocorticoids To Treat Pathologic Ocular Angiogenesis
view source
US Patent:

20040167109, Aug 26, 2004
Filed:

Feb 5, 2004
Appl. No.:

10/772963
Inventors:

David Bingaman - Fort Worth TX, US
Abbot Clark - Arlington TX, US
Rajni Jani - Fort Worth TX, US
Stella Robertson - Fort Worth TX, US
International Classification:

A61K031/58
A61K031/573
US Classification:

514/176000, 514/179000
Abstract:

Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema.

Use Of Steroids To Treat Persons Suffering From Ocular Disorders
view source
US Patent:

20040171598, Sep 2, 2004
Filed:

Feb 4, 2004
Appl. No.:

10/771829
Inventors:

David Bingaman - Fort Worth TX, US
Abbot Clark - Arlington TX, US
Rajni Jani - Fort Worth TX, US
Stella Robertson - Fort Worth TX, US
International Classification:

A61K031/573
US Classification:

514/179000
Abstract:

Methods and compositions for treating retinal edema and NPDR are disclosed.

Triamcinolone Acetonide And Anecortave Acetate Formulations For Injection
view source
US Patent:

20050065137, Mar 24, 2005
Filed:

Sep 2, 2004
Appl. No.:

10/933006
Inventors:

Rajni Jani - Fort Worth TX, US
Ernesto Castillo - Arlington TX, US
Wesley Han - Arlington TX, US
International Classification:

A61K031/56
US Classification:

514171000
Abstract:

Injectable compositions of triamcinolone acetonide or anecortave acetate are disclosed. The compositions are particularly suitable for injection into the posterior segment of the eye to treat ophthalmic diseases.

Formulations Of Glucocorticoids To Treat Pathologic Ocular Angiogenesis
view source
US Patent:

20060074061, Apr 6, 2006
Filed:

Feb 5, 2004
Appl. No.:

10/545053
Inventors:

David Bingaman - Fort Worth TX, US
Abbot Clark - Arlington TX, US
Rajni Jani - Fort Worth TX, US
Stella Robertson - Fort Worth TX, US
International Classification:

A61K 31/573
US Classification:

514179000
Abstract:

Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema

Self-Preserved Ophthalmic Pharmaceutical Compositions Containing Tobramycin
view source
US Patent:

20060141059, Jun 29, 2006
Filed:

Dec 23, 2005
Appl. No.:

11/317261
Inventors:

Masood Chowhan - Arlington TX, US
Ernesto Castillo - Arlington TX, US
Glenn Stafford - Burleson TX, US
Rajni Jani - Fort Worth TX, US
Haresh Bhagat - Fort Worth TX, US
International Classification:

A61K 31/7034
A61K 33/22
US Classification:

424660000, 514038000
Abstract:

Self-preserved, multi-dose ophthalmic compositions containing tobramycin are described. The compositions do not contain a conventional antimicrobial preservative, such as benzalkonium chloride. Rather, the compositions are self-preserved as a result of the inherent antimicrobial activity of tobramycin. The compositions preferably also contain either boric acid or, more preferably, a borate/polyol complex selected from the group consisting of borate/propylene glycol, borate/glycerol, and combinations thereof.